Nova Eye Medical (ASX:EYE): iTrack Advance and the Expansion of Glaucoma Care

Aditi Sarkar

12 October 2026 05:44 PM AEDT

Nova Eye Medical (ASX:EYE): iTrack Advance and the Expansion of Glaucoma Care

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Nova Eye Medical develops medical devices for interventional glaucoma treatment.
iTrack Advance is central to its canaloplasty product portfolio and clinical education activities.
Company disclosures in 2026 covered sales performance and European regulatory certification.
Growth in US device adoption sits alongside reimbursement and surgeon-training considerations.
Commercial expansion and Operating Cash Flow remain relevant to its financial profile.

Nova Eye Medical Limited (ASX:EYE) develops and manufactures ophthalmic devices used in glaucoma procedures. Its portfolio includes the iTrack family of canaloplasty instruments and the Molteno3 glaucoma drainage device, supported by surgeon education and in-house manufacturing. During 2026, the company reported progress in product sales, regulatory requirements and clinical evidence as it continued expanding its interventional glaucoma business.

iTrack Advance and Glaucoma Procedures

The iTrack Advance system is designed for canaloplasty, a procedure that accesses and dilates the eye’s conventional drainage pathway to help reduce intraocular pressure in patients with open-angle glaucoma. The device uses an illuminated microcatheter and viscodilation technique. Nova Eye Medical (ASX:EYE) markets the technology as part of a surgical toolkit that may be used according to patient needs and applicable regulatory indications.

Unlike a pharmaceutical therapy, the device is deployed by appropriately trained ophthalmic surgeons. Clinical adoption therefore involves procedural training, equipment availability and assessment of published evidence. These factors help distinguish Nova Eye Medical (ASX:EYE) from drug-development businesses that depend primarily on clinical trial approvals before commercialisation.

Sales Activity and 2026 Regulatory Milestones

In its February 2026 half-year update, the company reported sales Revenue excluding China of US$19.9 million for the 12 months to 31 December 2025, representing 28% growth over the corresponding period. The same release stated that underlying operating cash outflow for H1 FY26 was A$1.2 million, an improvement of A$2.4 million from the prior comparable half. These figures cover different reporting measures and should not be treated as interchangeable.

Nova Eye Medical (ASX:EYE) also announced European Union Medical Device Regulation certification in March 2026. Such certification relates to device conformity requirements; it should not be interpreted as a new clinical efficacy finding. The company’s own product information identifies US FDA clearance for the iTrack Advance system, subject to specified indications and precautions.

The group’s 2026 company-announcement calendar additionally records an updated sales-guidance announcement in May and FY26 financial reports released in August. For Nova Eye Medical (ASX:EYE), device revenue, regional sales mix and execution of Manufacturing and distribution plans are more directly relevant than speculative forecasts about an unapproved drug pipeline.

Commercial Considerations and Operating Risks

Commercial development depends on the pace at which surgeons and treatment centres adopt canaloplasty, the availability of reimbursement arrangements and the ability to maintain consistent device supply. Competing glaucoma treatment methods and local procedural guidelines also influence the environment in which iTrack Advance is used.

Operating expenditure is another consideration. Nova Eye Medical (ASX:EYE) must fund manufacturing, commercial support, Training and ongoing product-development activities while managing cash generation. Its 2026 reports provide a basis for assessing these factors without relying on share-price movements or promotional assessments of the market.

Key Insights

Nova Eye Medical (ASX:EYE) operates in a specialised medical-device segment where commercial progress depends on clinical use, regulatory compliance and surgeon familiarity. The iTrack Advance portfolio provides a clear product focus, while 2026 disclosures highlight the interaction between sales growth, geographic expansion and cash management. The company’s financial reports and subsequent product announcements remain the appropriate reference points for evaluating operational progress.

FAQs

Q:What does Nova Eye Medical manufacture?

A:It develops ophthalmic devices for glaucoma treatment, including iTrack canaloplasty systems and Molteno3 drainage devices.

Q:What is iTrack Advance used for?

A:It is a canaloplasty device designed for specified surgical applications involving the eye’s drainage pathway.

Q:What did the company report in its February 2026 update?

A:It disclosed 28% growth in 12-month sales excluding China to 31 December 2025 and improved underlying H1 FY26 operating cash outflow.

Q:What was the regulatory development in March 2026?

A:The company announced European Union Medical Device Regulation certification.

Q:Which operating factors are relevant?

A:Device adoption, reimbursement, training, manufacturing reliability and cash management are central commercial considerations.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.